Media headlines about Bristol-Myers Squibb (NYSE:BMY) have trended somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a news impact score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.1608876050294 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- VHT, ABBV, BMY, DHR: ETF Outflow Alert – Nasdaq (nasdaq.com)
- Bristol-Myers Squibb (BMY) Presents at Cowen and Company 38th Annual Health Care Conference (Transcript) – Seeking Alpha (seekingalpha.com)
- Biohaven Pharma restructures license agreement with Bristol-Myers; shares down 3% on discounted stock deal (seekingalpha.com)
- The Klein Law Firm Reminds Investors of a Class Action on Behalf of Bristol-Myers Squibb Company Shareholders and a Lead Plaintiff Deadline of April 10, 2018 (finance.yahoo.com)
- INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bristol-Myers Squibb Company And Encourages Investors With Losses To Contact The Firm (finance.yahoo.com)
Several research analysts have recently issued reports on BMY shares. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a report on Tuesday, December 5th. TheStreet cut shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a report on Thursday, March 8th. Credit Suisse Group set a $62.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, January 22nd. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, January 19th. Finally, Vetr upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 price objective for the company in a report on Thursday, February 1st. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $66.30.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period last year, the firm posted $0.63 earnings per share. The firm’s revenue for the quarter was up 3.9% compared to the same quarter last year. research analysts predict that Bristol-Myers Squibb will post 3.21 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is 67.80%.
In other news, Director Theodore R. Samuels II acquired 4,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average price of $62.30 per share, with a total value of $249,200.00. Following the purchase, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.23% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb (BMY) Receiving Somewhat Positive News Coverage, Accern Reports” was first posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/13/bristol-myers-squibb-bmy-receiving-somewhat-positive-news-coverage-accern-reports/2025347.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.